Cargando…

Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study

PURPOSE: Voriconazole (VRC) is an antifungal agent which is used for treatment and prophylaxis of invasive fungal infections. The common clinical adverse reactions mainly include central nervous system (CNS) toxicity and abnormal liver function. These adverse reactions limit the clinical use of vori...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Luting, Wang, Chuhui, Zhang, Yijing, Wang, Quanfang, Qiu, Yulan, Li, Sihan, Yang, Bo, Du, Qian, Chen, Jiaojiao, Teng, Mengmeng, Wang, Taotao, Dong, Yalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766498/
https://www.ncbi.nlm.nih.gov/pubmed/36561883
http://dx.doi.org/10.2147/IDR.S391022
_version_ 1784853744727359488
author Yang, Luting
Wang, Chuhui
Zhang, Yijing
Wang, Quanfang
Qiu, Yulan
Li, Sihan
Yang, Bo
Du, Qian
Chen, Jiaojiao
Teng, Mengmeng
Wang, Taotao
Dong, Yalin
author_facet Yang, Luting
Wang, Chuhui
Zhang, Yijing
Wang, Quanfang
Qiu, Yulan
Li, Sihan
Yang, Bo
Du, Qian
Chen, Jiaojiao
Teng, Mengmeng
Wang, Taotao
Dong, Yalin
author_sort Yang, Luting
collection PubMed
description PURPOSE: Voriconazole (VRC) is an antifungal agent which is used for treatment and prophylaxis of invasive fungal infections. The common clinical adverse reactions mainly include central nervous system (CNS) toxicity and abnormal liver function. These adverse reactions limit the clinical use of voriconazole to a certain extent. Therefore, the aim of this study was to analyze the risk factors of voriconazole neurotoxic side effects and to determine the plasma trough concentration (C(min)) threshold of voriconazole-induced CNS toxicity, so as to improve the safety of voriconazole treatment. PATIENTS AND METHODS: This study retrospectively collected the clinical data of 165 patients who received voriconazole and underwent therapeutic drug monitoring (TDM). CNS toxicity was defined using the National Cancer Institute (NCI) criteria, logistic regression was used to analyze the risk factors of CNS toxicity, classification and Regression tree (CART) model was used to determine the C(min) threshold for CNS toxicity. RESULTS: Voriconazole-related CNS toxicity occurred during treatment in 34 of 165 patients (20.6%) and the median time from administration to onset of CNS toxicity was 6 days (range, 2–19 days). The overall incidence of CNS toxicity was 20.6% (34/165), including visual disturbances in 4.8% (8/165) and nervous system disorders in 15.8% (26/165). C(min) significantly affects the occurrence of CNS toxicity and the threshold of C(min) for voriconazole CNS toxicity was determined to be 4.85 mg/L, when C(min) >4.85 mg/L and ≤4.85 mg/L, the incidence of CNS was 32.9% and 11.6%, respectively. CONCLUSION: Voriconazole trough concentration of C(min) is an independent risk factor for CNS toxicity, and the threshold of C(min) for CNS toxicity is 4.85mg/L. TDM should be routinely performed in patients with clinical use of voriconazole to reduce the occurrence of CNS toxicity of voriconazole.
format Online
Article
Text
id pubmed-9766498
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97664982022-12-21 Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study Yang, Luting Wang, Chuhui Zhang, Yijing Wang, Quanfang Qiu, Yulan Li, Sihan Yang, Bo Du, Qian Chen, Jiaojiao Teng, Mengmeng Wang, Taotao Dong, Yalin Infect Drug Resist Original Research PURPOSE: Voriconazole (VRC) is an antifungal agent which is used for treatment and prophylaxis of invasive fungal infections. The common clinical adverse reactions mainly include central nervous system (CNS) toxicity and abnormal liver function. These adverse reactions limit the clinical use of voriconazole to a certain extent. Therefore, the aim of this study was to analyze the risk factors of voriconazole neurotoxic side effects and to determine the plasma trough concentration (C(min)) threshold of voriconazole-induced CNS toxicity, so as to improve the safety of voriconazole treatment. PATIENTS AND METHODS: This study retrospectively collected the clinical data of 165 patients who received voriconazole and underwent therapeutic drug monitoring (TDM). CNS toxicity was defined using the National Cancer Institute (NCI) criteria, logistic regression was used to analyze the risk factors of CNS toxicity, classification and Regression tree (CART) model was used to determine the C(min) threshold for CNS toxicity. RESULTS: Voriconazole-related CNS toxicity occurred during treatment in 34 of 165 patients (20.6%) and the median time from administration to onset of CNS toxicity was 6 days (range, 2–19 days). The overall incidence of CNS toxicity was 20.6% (34/165), including visual disturbances in 4.8% (8/165) and nervous system disorders in 15.8% (26/165). C(min) significantly affects the occurrence of CNS toxicity and the threshold of C(min) for voriconazole CNS toxicity was determined to be 4.85 mg/L, when C(min) >4.85 mg/L and ≤4.85 mg/L, the incidence of CNS was 32.9% and 11.6%, respectively. CONCLUSION: Voriconazole trough concentration of C(min) is an independent risk factor for CNS toxicity, and the threshold of C(min) for CNS toxicity is 4.85mg/L. TDM should be routinely performed in patients with clinical use of voriconazole to reduce the occurrence of CNS toxicity of voriconazole. Dove 2022-12-16 /pmc/articles/PMC9766498/ /pubmed/36561883 http://dx.doi.org/10.2147/IDR.S391022 Text en © 2022 Yang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Luting
Wang, Chuhui
Zhang, Yijing
Wang, Quanfang
Qiu, Yulan
Li, Sihan
Yang, Bo
Du, Qian
Chen, Jiaojiao
Teng, Mengmeng
Wang, Taotao
Dong, Yalin
Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study
title Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study
title_full Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study
title_fullStr Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study
title_full_unstemmed Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study
title_short Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study
title_sort central nervous system toxicity of voriconazole: risk factors and threshold – a retrospective cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766498/
https://www.ncbi.nlm.nih.gov/pubmed/36561883
http://dx.doi.org/10.2147/IDR.S391022
work_keys_str_mv AT yangluting centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT wangchuhui centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT zhangyijing centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT wangquanfang centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT qiuyulan centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT lisihan centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT yangbo centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT duqian centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT chenjiaojiao centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT tengmengmeng centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT wangtaotao centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy
AT dongyalin centralnervoussystemtoxicityofvoriconazoleriskfactorsandthresholdaretrospectivecohortstudy